• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

Professional Introduction to Compound with CAS No. 1005631-76-4 and Product Name: 2-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanehydrazide

The compound with the CAS number 1005631-76-4 and the product name 2-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanehydrazide represents a significant advancement in the field of pharmaceutical chemistry. This compound, characterized by its unique molecular structure, has garnered considerable attention due to its potential applications in drug development and medicinal research. The presence of multiple functional groups, including difluoromethyl, methyl, and hydrazide, makes it a versatile intermediate in synthesizing complex molecules with therapeutic properties.

In recent years, the pharmaceutical industry has witnessed a surge in the exploration of novel heterocyclic compounds, particularly those containing pyrazole moieties. Pyrazole derivatives are known for their broad spectrum of biological activities, making them valuable candidates for further investigation. The specific structure of 2-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanehydrazide positions it as a promising candidate for developing new drugs targeting various diseases. The difluoromethyl group, in particular, is a key feature that enhances the metabolic stability and bioavailability of the compound, which is crucial for its efficacy as a drug.

Current research in medicinal chemistry has highlighted the importance of hydrazide derivatives in the development of anti-inflammatory, anti-tumor, and anti-microbial agents. The hydrazide functional group in this compound provides a reactive site for further chemical modifications, enabling the synthesis of more complex molecules with enhanced pharmacological properties. Studies have shown that hydrazide-containing compounds can interact with biological targets in multiple ways, leading to potent therapeutic effects. This makes 2-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanehydrazide a valuable tool in the quest for new pharmacological agents.

The synthesis of this compound involves a series of well-defined chemical reactions that highlight the expertise required in organic synthesis. The introduction of the difluoromethyl group and the methyl substituent at specific positions on the pyrazole ring requires precise control over reaction conditions to ensure high yield and purity. Advanced synthetic techniques, such as cross-coupling reactions and transition metal catalysis, are often employed to achieve these objectives. The success of these synthetic approaches underscores the importance of cutting-edge methodologies in modern pharmaceutical research.

One of the most intriguing aspects of 2-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanehydrazide is its potential application in targeting specific biological pathways associated with various diseases. For instance, preliminary studies have suggested that this compound may exhibit inhibitory effects on enzymes involved in inflammation and cancer progression. The difluoromethyl group is known to enhance binding affinity to biological targets, which could improve the compound's efficacy as a drug candidate. Additionally, the presence of multiple functional groups allows for further derivatization, enabling researchers to fine-tune its pharmacological properties.

The role of computational chemistry in understanding the behavior of complex molecules like 2-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanehydrazide cannot be overstated. Molecular modeling techniques provide insights into how this compound interacts with biological targets at the molecular level. These studies help predict its pharmacokinetic properties and potential side effects, which are critical factors in drug development. By leveraging computational tools, researchers can optimize the structure of this compound to enhance its therapeutic potential while minimizing adverse effects.

In conclusion, 2-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanehydrazide represents a significant advancement in pharmaceutical chemistry with potential applications across multiple therapeutic areas. Its unique molecular structure, characterized by functional groups such as difluoromethyl, methyl, and hydrazide, makes it a versatile intermediate for synthesizing novel drugs. Ongoing research continues to uncover new possibilities for this compound, highlighting its importance in modern medicinal chemistry. As our understanding of biological pathways grows, compounds like this one will play an increasingly crucial role in developing next-generation therapeutics.

• 1005592-15-3(2-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanehydrazide)
• 1005695-50-0(2-(3-Methyl-1H-pyrazol-1-yl)propanohydrazide)
• 512810-15-0(2-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylacetohydrazide)
• 1005614-37-8(2-(5-methyl-1H-pyrazol-1-yl)propanehydrazide)
• 1001518-87-1(2-3,5-bis(difluoromethyl)-1H-pyrazol-1-ylacetohydrazide)
• 1005651-08-0(2-4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanehydrazide)
• 1251929-87-9(2-(3,5-Dimethyl-1H-pyrazol-1-yl)propanohydrazide)
• 1006327-06-5(2-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanehydrazide)
• 1005650-83-8(2-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanehydrazide)
• 1001518-82-6(2-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylacetohydrazide)